$BRVE
Braveheart Bio, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$21.19
▲+4.54%+$0.920
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateBraveheart Bio, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is BRVE up today? It is at $21.19 (+4.54%), and our scanner flagged it 84 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment BRVE spikes, and full due diligence on BRVE — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $BRVE 84 times in the last 30 days. Create a free account to track $BRVE, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on BRVE from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for BRVE today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystBraveheart Bio, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13D/AActivist 5%+ stake updatedSep 10, 2026 · 40 days ago* Institutional ownership was unavailable, so float is insider-deduped only.
A share sale has already completed, so that supply is out there. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Lubner David Charles Director | Bought (open market) | +56K 0.06% of company | n/a | 56K | $1000K at $18.00 | Aug 7, 26 |
Murdoch Travis Officer | Bought (open market) | +83K 0.09% of company | added 2.9% | 2.94M | $1.5M at $18.00 | Aug 7, 26 |
Anderson Michele A. Officer | Bought (open market) | +1K | added 0.3% | 332K | $20K at $18.00 | Aug 7, 26 |
Viehbacher Christopher Director | Bought (open market) | +83K 0.09% of company | added 16% | 610K | $1.5M at $18.00 | Aug 7, 26 |
Malek David I Director | Bought (open market) | +4K | added 0.8% | 534K | $75K at $18.00 | Aug 7, 26 |
Rickey James Paul Officer | Bought (open market) | +28K 0.03% of company | added 5.6% | 521K | $500K at $18.00 | Aug 7, 26 |
Forbion Growth Opportunities Fund Iii Cooperatief U.A. Beneficial Owner (10%) | Acquired (grant/award) | +9.13M 10.1% of company | added 100% | 9.72M | n/a | Aug 7, 26 |
Forbion Growth Opportunities Fund Iii Cooperatief U.A. Beneficial Owner (10%) | Acquired (grant/award) | +7.99M 8.9% of company | added 100% | 8.51M | n/a | Aug 7, 26 |
Forbion Growth Opportunities Fund Iii Cooperatief U.A. Beneficial Owner (10%) | Bought (open market) | +1.92M 2.1% of company | added 20% | 11.64M | $34.6M at $18.00 | Aug 7, 26 |
Forbion Growth Opportunities Fund Iii Cooperatief U.A. Beneficial Owner (10%) | Bought (open market) | +1.68M 1.9% of company | added 20% | 10.19M | $30.2M at $18.00 | Aug 7, 26 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Beneficial Owner (10%) | Acquired (grant/award) | +7.42M 8.2% of company | n/a | 7.42M | n/a | Aug 7, 26 |
Orbimed Advisors Llc Director | Acquired (grant/award) | +9.13M 10.1% of company | added 100% | 10.24M | n/a | Aug 7, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on BRVE from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for BRVE today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
BRVE last traded at $21.19, up 4.54% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Braveheart Bio, Inc. Common Stock (BRVE) is next expected to report earnings on Tuesday, December 8, 2026, about 48 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The BRVE Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged BRVE 84 times in the last 30 days.
BRVE (Braveheart Bio, Inc. Common Stock) trades on XNAS, with a market cap of about $1.83B in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge BRVE for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$BRVE discussion
Sign in to ask a question or join the discussion.